HEPION PHARMACEUTICALS, INC. Notes Payable, Current
HEPION PHARMACEUTICALS, INC. (HEPA) had Notes Payable, Current of $54.07 thousand as of 2025-12-31, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:NotesPayableCurrent · last filed 2026-08-13
- 2025-12-31: Notes Payable, Current $54.07K.
- 2025-09-30: Notes Payable, Current $214.31K.
- 2025-06-30: Notes Payable, Current $371.66K.
- 2025-03-31: Notes Payable, Current $526.18K.
| Period end | Notes Payable, Current |
|---|---|
| 2025-12-31 | $54.07K 10-Q · filed 2026-08-13 |
| 2025-09-30 | $214.31K 10-Q · filed 2025-11-12 |
| 2025-06-30 | $371.66K 10-Q · filed 2025-08-14 |
| 2025-03-31 | $526.18K 10-Q · filed 2025-05-19 |
| 2024-12-31 | $2.90M 10-K · filed 2026-03-12 |
| 2024-09-30 | $2.11M 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |